Paul Richardson
Overview
Explore the profile of Paul Richardson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
396
Citations
20176
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sun J, Peter A, He J, Tsien J, Zhang H, Cagan D, et al.
Science
. 2025 Mar;
:eadu6406.
PMID: 40048551
No abstract available.
2.
Richardson P, Beksac M, Oriol A, Lindsay J, Schjesvold F, Galli M, et al.
Eur J Haematol
. 2025 Jan;
PMID: 39777934
Introduction: In the OPTIMISMM trial, pomalidomide/bortezomib/dexamethasone (PVd) significantly prolonged median progression-free survival (PFS) versus bortezomib/dexamethasone (Vd) in lenalidomide-exposed relapsed and refractory multiple myeloma (RRMM). We report final overall survival (OS)...
3.
McDonald A, Das A, Twamley B, Kelly O, Kelly O, Panda C, et al.
Angew Chem Int Ed Engl
. 2024 Dec;
64(10):e202421157.
PMID: 39688219
The heme paradigm where Fe=O acts as the C-H oxidant and Fe-OH rebounds with the formed carbon-centered radical guides the design of the prototypical synthetic hydroxylation catalyst. We are exploring...
4.
Gallego R, Cho-Schultz S, Del Bel M, Dechert-Schmitt A, Donaldson J, He M, et al.
J Med Chem
. 2024 Dec;
67(24):22002-22038.
PMID: 39651809
Hematopoietic progenitor kinase 1 (HPK1/MAP4K1) represents a high interest target for the treatment of cancer through an immune-mediated mechanism. Herein we present highlights of the drug discovery campaign within the...
5.
Gallego R, Scales S, Toledo C, Auth M, Bernier L, Berry M, et al.
J Med Chem
. 2024 Nov;
67(21):19234-19246.
PMID: 39499084
By virtue of its role in cellular proliferation, microtubule-associated serine/threonine kinase-like (MASTL) represents a novel target and a first-in-class (FIC) opportunity to provide a new impactful therapeutic agent to oncology...
6.
Fogel J, Persaud D, Piwowar-Manning E, Richardson P, Szewczyk J, Marzinke M, et al.
AIDS Res Hum Retroviruses
. 2024 Oct;
41(1):30-36.
PMID: 39466048
We evaluated HIV DNA levels in individuals who received long-acting cabotegravir (CAB-LA) or tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) pre-exposure prophylaxis in the HPTN 083 and 084 trials and had HIV DNA...
7.
Conti R, McCue S, Dockter T, Gunn H, Dusetzina S, Bennett A, et al.
medRxiv
. 2024 Oct;
PMID: 39371185
Objectives: To estimate the proportion and correlates of self-reported financial difficulty among patients with multiple myeloma (MM) or chronic lymphocytic leukemia (CLL). Setting: 23 U.S. community and minority oncology practice...
8.
Richardson P, Htut M, Scott E, Prada C, Gupta I
Haematologica
. 2024 Oct;
110(2):488-492.
PMID: 39363849
No abstract available.
9.
Bolt R, Smallman H, Leitch J, Bluck G, Barreteau F, Iosub A, et al.
Angew Chem Int Ed Engl
. 2024 Sep;
63(41):e202408315.
PMID: 39248684
Herein, we report on the translation of a small scale ball-milled amidation protocol into a large scale continuous reactive extrusion process. Critical components to the successful translation were: a) understanding...
10.
Vergis N, Patel V, Bogdanowicz K, Czyzewska-Khan J, Keshinro R, Fiorentino F, et al.
Clin Gastroenterol Hepatol
. 2024 Aug;
PMID: 39181422
Background And Aims: Short-term mortality in alcohol-related hepatitis (AH) is high, and no current therapy results in durable benefit. A role for interleukin (IL)-1β has been demonstrated in the pathogenesis...